Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Merve Uça Apaydın has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Network-guided identification and multi-targeting of cell cycle regulatory hubs in obesity-linked colorectal cancer

    by Merve Uça Apaydın, Hüseyin Güner, Reşat Ünal, Halil İbrahim Pazarbaşı, Alexandros G Georgakılas, Athanasia Pavlopoulou

    Purpose: Obesity-associated colorectal cancer (CRC) involves complex molecular networks that limit the effectiveness of single-target therapies. This study aimed to develop an integrative computational pipeline for identifying key regulatory hubs and designing a multi-target-directed ligand (MTDL) capable of simultaneously modulating critical components of the CRC interactome.Materials and Methods: Differential gene expression analysis between CRC and corresponding healthy tissue-derived samples identified upregulated genes in colon adenocarcinoma. A high-confidence protein–protein interaction network was constructed from these genes to identify central hub proteins using topological analysis. To target these hubs, structure-based de novo ligand design and molecular docking were employed to evaluate binding affinities and multi-target potential. Finally, the candidate MTDL underwent in silico pharmacokinetic (ADME) and toxicity profiling, supplemented by a similarity search within natural compound libraries.Results: A total of 786 upregulated genes were identified, of which 204 formed a dense functional interactome. Three central hubs (CDC6, CCNB1, and CDC25C), all critical to cell cycle regulation, were prioritized as therapeutic targets. The designed MTDL demonstrated favorable binding affinities across all targets, interacting with functionally conserved domains. Furthermore, the ligand exhibited a favorable drug-like profile, characterized by high gastrointestinal absorption and a low toxicity risk. Screening of natural product libraries yielded several analogs with comparable binding profiles, supporting the chemical feasibility of the proposed scaffold.Conclusion: This study presents a network-guided framework for multi-target drug design in CRC. By shifting from a "one-target, one-drug" model to a systems-level approach, the proposed MTDL and its natural analogs represent promising candidates for experimental validation in the treatment of complex, obesity-associated CRC.

  • Open Access

    Computer-Aided Identification and Design of Ligands for Multi-Targeting Inhibition of a Molecular Acute Myeloid Leukemia Network

    by Seyedeh Sadaf Asfa, Reza Arshinchi Bonab, Onur Önder, Merve Uça Apaydın, Hatice Döşeme, Can Küçük, Alexandros G. Georgakilas, Bernhard M. Stadler, Stella Logotheti, Seyit Kale, et al.

    Background/Objectives: Acute myeloid leukemia (AML) is characterized by therapeutic failure and long-term risk for disease relapses. As several therapeutic targets participate in networks, they can rewire to eventually evade single-target drugs. Hence, multi-targeting approaches are considered on the expectation that interference with many different components could synergistically hinder activation of alternative pathways and demolish the network one-off, leading to complete disease remission. Methods: Herein, we established a network-based, computer-aided approach for the rational design of drug combinations and de novo agents that interact with many AML network components simultaneously. Results: A reconstructed AML network guided the selection of suitable protein hubs and corresponding multi-targeting strategies. For proteins responsive to existing drugs, a greedy algorithm identified the minimum amount of compounds targeting the maximum number of hubs. We predicted permissible combinations of amiodarone, artenimol, fostamatinib, ponatinib, procaine, and vismodegib that interfere with 3–8 hubs, and we elucidated the pharmacological mode of action of procaine on DNMT3A. For proteins that do not respond to any approved drugs, namely cyclins A1, D2, and E1, we used structure-based de novo drug design to generate a novel triple-targeting compound of the chemical formula C15H15NO5, with favorable pharmacological and drug-like properties. Conclusions: Overall, by integrating network and structural pharmacology with molecular modeling, we determined two complementary strategies with the potential to annihilate the AML network, one in the form of repurposable drug combinations and the other as a de novo synthesized triple-targeting agent. These target–drug interactions could be prioritized for preclinical and clinical testing toward precision medicine for AML.


  • Open Access

    Non-Hereditary Obesity Type Networks and New Drug Targets: An In Silico Approach

    by Styliani A. Geronikolou, Athanasia Pavlopoulou, Merve Uça Apaydin, Konstantinos Albanopoulos, Dennis V. Cokkinos, George Chrousos

    Obesity, a chronic, preventable disease, has significant comorbidities that are associated with a great human and financial cost for society. The aim of the present work is to reconstruct the interactomes of non-hereditary obesity to highlight recent advances of its pathogenesis, and discover potential therapeutic targets. Obesity and biological-clock-related genes and/or gene products were extracted from the biomedical literature databases PubMed, GeneCards and OMIM. Their interactions were investigated using STRING v11.0 (a database of known and predicted physical and indirect associations among genes/proteins), and a high confidence interaction score of >0.7 was set. We also applied virtual screening to discover natural compounds targeting obesity- and circadian-clock-associated proteins. Two updated and comprehensive interactomes, the (a) stress- and (b) inflammation-induced obesidomes involving 85 and 93 gene/gene products of known and/or predicted interactions with an average node degree of 9.41 and 10.8, respectively, were produced. Moreover, 15 of these were common between the two non-hereditary entities, namely, ADIPOQ, ADRB2/3, CCK, CRH, CXCL8, FOS, GCG, GNRH1, IGF1, INS, LEP, MC4R, NPY and POMC, while phelligridin E, a natural product, may function as a potent FOX1-DBD interaction blocker. Molecular networks may contribute to the understanding of the integrated regulation of energy balance/obesity pathogenesis and may associate chronopharmacology schemes with natural products.


  • Open Access

    Dual Targeting of DNA Damage Response Proteins Implicated in Cancer Radioresistance

    by Spyridon N. Vasilopoulos, Hüseyin Güner, Merve Uça Apaydın, Athanasia Pavlopoulou, Alexandros G. Georgakilas

    Ionizing radiation can induce different types of DNA lesions, leading to genomic instability and ultimately cell death. Radiation therapy or radiotherapy, a major modality in cancer treatment, harnesses the genotoxic potential of radiation to target and destroy cancer cells. Nevertheless, cancer cells have the capacity to develop resistance to radiation treatment (radioresistance), which poses a major obstacle in the effective management of cancer. It has been shown that administration of platinum-based drugs to cancer patients can increase tumor radiosensitivity, but despite this, it is associated with severe adverse effects. Several lines of evidence support that activation of the DNA damage response and repair machinery in the irradiated cancer cells enhances radioresistance and cellular survival through the efficient repair of DNA lesions. Therefore, targeting of key DNA damage repair factors would render cancer cells vulnerable to the irradiation effects, increase cancer cell killing, and reduce the risk of side effects on healthy tissue. Herein, we have employed a computer-aided drug design approach for generating ab initio a chemical compound with drug-like properties potentially targeting two proteins implicated in multiple DNA repair pathways. The findings of this study could be taken into consideration in clinical decision-making in terms of co-administering radiation with DNA damage repair factor-based drugs.


  • Open Access

    Electrochemical Investigation of Curcumin–DNA Interaction by Using Hydroxyapatite Nanoparticles–Ionic Liquids Based Composite Electrodes

    by Merve Uca, Ece Eksin, Yasemin Erac, Arzum Erdem

    Hydroxyapatite nanoparticles (HaP) and ionic liquid (IL) modified pencil graphite electrodes (PGEs) are newly developed in this assay. Electrochemical impedance spectroscopy (EIS), scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDX), and cyclic voltammetry (CV) were applied to examine the microscopic and electrochemical characterization of HaP and IL-modified biosensors. The interaction of curcumin with nucleic acids and polymerase chain reaction (PCR) samples was investigated by measuring the changes at the oxidation signals of both curcumin and guanine by differential pulse voltammetry (DPV) technique. The optimization of curcumin concentration, DNA concentration, and the interaction time was performed. The interaction of curcumin with PCR samples was also investigated by gel electrophoresis.